April 20, 2016
Research shines new light on malignant hyperthermia
The rare but very serious condition of malignant hyperthermia (MH) remains a risk at all surgical facilities, including ambulatory surgical centers (ASCs). MH occurs in about one in 50,000 adults under anesthesia, and one in about 12,000 children, which translates to one or two deaths annually in the United States. When it does strike, MH often is fatal if not treated within minutes. And the only antidote is a very expensive drug.
Free Daily News
- Study: COVID-19's impact on oncological surgery offers lessons for future crises
- Study links pandemic stress to persistent increases in nursing-sensitive quality indicators
- Save the date for the 2025 OR Business Management Conference
- Study: Education, exercise improve knee OA with or without prior surgery
- Study: Early surgery outperforms endoscopy for long-term pancreatitis
- Study: Blood thinner, NSAID combination raises bleeding risk
- Hospital financial report predicts stability, high cybersecurity costs for 2025
- IV fluid shortage drives innovation in hospital hydration practices
- FDA Class 1 recalls target anesthesia workstations, ambulatory infusion pumps, ventilators
- Five leadership lessons from an ASC CEO
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement